- Implemented Hyperinflation Management where hyperinflated drugs that have readily available, clinically appropriate and more cost-effective alternatives are excluded under the EUTF active plans.
- Implemented the Basic Control Formulary where utilization management was added to non-preferred products in ten specific drug classes under the EUTF active plans.
- Revised prior authorization criteria for coverage of antidiabetic GLP-1s (e.g. Ozempic, Mounjaro, Rybelsus, Trulicity, and Victoza) under the EUTF active plans.
- Added 100% coverage of Apretude and Descovy (in addition to generic Truvada) for HIV pre-exposure prophylaxis (PrEP) under the EUTF and HSTA VB active plans, in accordance with federal law. The brand name Truvada will still require an exception since it has a generic available.
CVS Active Benefits
What’s New?
Effective July 1, 2025:
For EUTF Members
For HSTA VB Members